Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: An eastern cooperative oncology group trial

Journal of Clinical Oncology

Volumn 31, Issue 11, 2013, Pages 1405-1414

  Argiris, Athanassios ^a   Ghebremichael, Musie ^b   Gilbert, Jill ^d   Lee, Ju Whei ^c   Sachidanandam, Kamakshi ^e   Kolesar, Jill M ^e   Burtness, Barbara ^f   Forastiere, Arlene A ^g  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e UNIVERSITY OF WISCONSIN MADISON   (United States)

^f FOX CHASE CANCER CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; K RAS PROTEIN; PLACEBO; SCATTER FACTOR RECEPTOR;

ABDOMINAL BLEEDING; ABDOMINAL INFECTION; ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGE DISTRIBUTION; AGED; ANOREXIA; APPENDIX FISTULA; ARTICLE; BLOODSTREAM INFECTION; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CAROTID ARTERY INJURY; COLITIS; COLON FISTULA; CONTROLLED STUDY; COUGHING; CYSTITIS; DESQUAMATION; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DUODENUM PERFORATION; DYSPHAGIA; DYSPNEA; EDEMA; ESOPHAGUS HEMORRHAGE; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FISTULA; GENETIC CORRELATION; GENETIC POLYMORPHISM; GENOTYPE; HAND FOOT SYNDROME; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE FLUTTER; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; HYPOXIA; INSOMNIA; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; LEUKOPENIA; LIMB WEAKNESS; LUNG HEMORRHAGE; LUNG INFILTRATE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOTOR NEUROPATHY; MUTATIONAL ANALYSIS; NAIL DISEASE; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; ORAL BLEEDING; ORAL MUCOSITIS; OVERALL SURVIVAL; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SENSORY NEUROPATHY; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; TRISMUS; VOMITING; WEIGHT REDUCTION; WHEEZING; WILD TYPE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DIARRHEA; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKOPENIA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MET; QUINAZOLINES; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TREATMENT OUTCOME;

EID: 84876073132     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.45.4272     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62:10-29, 2012
2. Argiris A, Li Y, Forastiere A: Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck. Cancer 101:2222-2229, 2004
3. Stewart JS, Cohen EE, Licitra L, et al: Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. J Clin Oncol 27:1864-1871, 2009
4. Hitt R, Amador ML, Quintela-Fandino M, et al: Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Cancer 106:106-111, 2006 (Pubitemid 43032554)
5. Guardiola E, Peyrade F, Chaigneau L, et al: Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer 40:2071-2076, 2004 (Pubitemid 39165540)
6. Vermorken JB, Trigo J, Hitt R, et al: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177, 2007 (Pubitemid 46954639)
7. Burtness B, Goldwasser MA, Flood W, et al: Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654, 2005 (Pubitemid 46211507)
8. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
9. Cohen EE, Kane MA, List MA, et al: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11:8418-8424, 2005 (Pubitemid 41746956)
10. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003 (Pubitemid 46606387)
11. Kirby AM, A'Hern RP, D'Ambrosio C, et al: Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 94:631-636, 2006 (Pubitemid 43361892)
12. Choe MS, Chen Z, Klass CM, et al: Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clin Cancer Res 13:3015-3023, 2007 (Pubitemid 46849578)
13. Klass CM, Choe MS, Hurwitz SJ, et al: Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer. Head Neck 31:1263-1273, 2009
14. Saigal B, Glisson BS, Johnson FM: Dose-dependent and sequence-dependent cytotoxicity of erlotinib and docetaxel in head and neck squamous cell carcinoma. Anticancer Drugs 19:465-475, 2008 (Pubitemid 351556398)
15. Belon J, Irigoyen A, Rodriguez I, et al: Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck. J Clin Oncol 23: 295s, 2005 (suppl; abstr 5563)
16. Kraut EH, Rhoades C, Zhang Y, et al: Phase I and pharmacokinetic study of erlotinib (OSI-774) in combination with docetaxel in squamous cell carcinoma of the head and neck (SSCHN). Cancer Chemother Pharmacol 67:579-586, 2011
17. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
18. Hama T, Yuza Y, Saito Y, et al: Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma. Oncologist 14:900-908, 2009
19. Ramalingam SS, Lee JW, Belani CP, et al: Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): An Eastern Cooperative Oncology Group phase II study (ECOG 1504). J Clin Oncol 29:1709-1714, 2011
20. Takano T, Ohe Y, Sakamoto H, et al: Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:6829-6837, 2005
21. Zhang X, Nagahara H, Mimori K, et al: Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib. Oncol Rep 19:1541-1544, 2008
22. Di Renzo MF, Olivero M, Martone T, et al: Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene 19:1547-1555, 2000 (Pubitemid 30175676)
23. Kong-Beltran M, Seshagiri S, Zha J, et al: Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 66:283-289, 2006 (Pubitemid 43166034)
24. Onozato R, Kosaka T, Kuwano H, et al: Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol 4:5-11, 2009
25. Schmidt L, Junker K, Nakaigawa N, et al: Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene 18:2343-2350, 1999 (Pubitemid 29192711)
26. Seiwert TY, Jagadeeswaran R, Faoro L, et al: The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res 69:3021-3031, 2009
27. Ogino S, Meyerhardt JA, Irahara N, et al: KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 15:7322-7329, 2009
28. Pao W, Wang TY, Riely GJ, et al: KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17, 2005
29. Weber A, Langhanki L, Sommerer F, et al: Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 22:4757-4759, 2003 (Pubitemid 36976451)
30. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979 (Pubitemid 10242750)
31. Jennison C, Turnbull BW: Statistical approaches to interim monitoring of medical trials: A review and commentary. Statistical Science 5:299-317, 1990
32. Cox DR, Snell EJ: Analysis of binary data (ed 2). London, United Kingdom, Chapman and Hall, 1989
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Amer Stat Assn 53:457-481, 1958
34. Cox DR: Regression models and life-tables. J R Stat Soc Series B Stat Methodol 34:187-220, 1972
35. Argiris A, Li Y, Murphy BA, et al: Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 22:262-268, 2004 (Pubitemid 41095090)
36. Hurria A, Togawa K, Mohile SG, et al: Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 29:3457-3465, 2011
37. Kimmick GG, Fleming R, Muss HB, et al: Cancer chemotherapy in older adults: A tolerability perspective. Drugs Aging 10:34-49, 1997 (Pubitemid 27057936)
38. Argiris A, Buchanan A, Brockstein B, et al: Docetaxel and irinotecan in recurrent or metastatic head and neck cancer: A phase 2 trial of the Eastern Cooperative Oncology Group. Cancer 115:4504-4513, 2009
39. Kim ES, Kies MS, Glisson BS, et al: Phase II study of combination cisplatin, docetaxel and erlotinib in patients with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 24: 285s, 2006 (suppl; abstr 5521)
40. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007 (Pubitemid 46972777)
41. Giaccone G, Herbst RS, Manegold C, et al: Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 1. J Clin Oncol 22:777-784, 2004 (Pubitemid 41103588)
42. Herbst RS, Giaccone G, Schiller JH, et al: Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: A phase III trial - INTACT 2. J Clin Oncol 22:785-794, 2004 (Pubitemid 41103589)
43. Herbst RS, Prager D, Hermann R, et al: TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899, 2005
44. Gatzemeier U, Pluzanska A, Szczesna A, et al: Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552, 2007 (Pubitemid 46733081)
45. Davies AM, Ho C, Beckett L, et al: Intermittent erlotinib in combination with pemetrexed: Phase I schedules designed to achieve pharmacodynamic separation. J Thorac Oncol 4:862-868, 2009
46. Chau NG, Perez-Ordonez B, Zhang K, et al: The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Head Neck Oncol 3:11, 2011
47. Lim EH, Zhang SL, Li JL, et al: Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol 4:12-21, 2009
48. Ludovini V, Bianconi F, Pistola L, et al: Optimization of patient selection for EGFR-TKIs in advanced non-small cell lung cancer by combined analysis of KRAS, PIK3CA, MET, and non-sensitizing EGFR mutations. Cancer Chemother Pharmacol 69:1289-1299, 2012
49. McIntyre JB, Bose P, Klimowicz AC, et al: Specific and sensitive hydrolysis probe-based realtime PCR detection of epidermal growth factor receptor variant III in oral squamous cell carcinoma. PLoS One 7:e31723, 2012